COMMUNIQUÉS West-GlobeNewswire

-
BioSenic patent granted in Canada for broader protection of ATO therapeutic platform
30/01/2024 -
Le brevet de BioSenic est accordé au Canada pour une protection plus large de sa plate-forme thérapeutique ATO
30/01/2024 -
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
30/01/2024 -
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
30/01/2024 -
Among the ongoing attacks on Ukraine, religious leaders aim to unite the Ukrainian religious diaspora and foster collaboration between Ukraine and the U.S. through Ukrainian Week 2024
30/01/2024 -
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
29/01/2024 -
Castellum Announces Closing of $2.7 Million Registered Direct Offering
29/01/2024 -
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
29/01/2024 -
Dentsply Sirona to Host Fourth Quarter and Full Year 2023 Conference Call on February 29th
29/01/2024 -
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
29/01/2024 -
Nanobiotix annonce l’atteinte des conditions pour un paiement d'étape de développement de 20 M$ lié à l'étude mondiale de phase 3 en cours sur le cancer de la tête et du cou
29/01/2024 -
Immunocore Announces Proposed Convertible Senior Notes Offering
29/01/2024 -
Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024
29/01/2024 -
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/01/2024 -
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
29/01/2024 -
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
29/01/2024 -
Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference
29/01/2024 -
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
29/01/2024 -
Range Impact Announces Former Ohio Congressman Zack Space and Former Ohio Senator Jay Hottinger Have Joined the Company as Strategic Advisors
29/01/2024
Pages